AstraZeneca: Myasthenia Gravis trials

The registry lists 19 Myasthenia Gravis studies with AstraZeneca as lead sponsor. 8 are open to participants now and 6 have results posted.

Phase 2 3Phase 3 9Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)RecruitingNCT07596784Phase 3
• Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in RussiaRecruitingNCT07247279
• A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabRecruitingNCT07221838Phase 4
• Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia GravisRecruitingNCT06967480
• Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia GravisRecruitingNCT06909253
• PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisRecruitingNCT06607627Phase 3
• Study of Ultomiris® (Ravulizumab) Safety in PregnancyRecruitingNCT06312644
• Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)RecruitingNCT04202341
• Study of ALXN2050 in Adult Participants With Generalized Myasthenia GravisTerminatedNCT05218096Phase 2Results posted
• Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia GravisCompletedNCT03920293Phase 3Results posted
• A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)CompletedNCT03759366Phase 3Results posted
• Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia GravisCompletedNCT02301624Phase 3Results posted
• Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)CompletedNCT01997229Phase 3Results posted
• Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia GravisTerminatedNCT00727194Phase 2Results posted
• Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMGCompletedNCT06764160Phase 3
• A Study in Patients With Myasthenia Gravis in ChinaActive, not recruitingNCT06700616
• Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisActive, not recruitingNCT05644561Phase 3
• Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia GravisActive, not recruitingNCT05556096Phase 3
• Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia GravisWithdrawnNCT04982289Phase 2